Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV open-label single-arm study of recombinant human growth hormone injection for short stature in children with achondroplasia
CTR20221405Phase 4Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of somatropin in achondroplasia (ACH), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Sep 2022; status: completed.
02
Drugs
somatropin
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on CTR20221405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221405.